KLRC1 and cancer: Inaddition, structure-based foundation is now provided for the utilizationof the NKG2A/CD94/HLA-E/β-2m/peptide immune complex in drugdiscovery against diverse pathologies including viral infections,cancer, and the elimination of senescent cells, a potential new therapeuticapproach for many age-related diseases.